New pancreatic cancer drug might open the door to much longer survival times

Original Article ↗ Hacker News Discussion ↗

A new targeted drug, daraxonrasib, is showing striking early results against pancreatic tumors driven by KRAS mutations, a pathway long considered “undruggable” and present in roughly 20% of cancers. Commenters highlight how the drug’s novel mechanism — effectively “gluing” KRAS to another protein to shut down growth signals — could open a whole class of therapies for otherwise lethal cancers, while stressing that benefits so far are measured in added months of life and will depend heavily on cancer type and combination treatments. The exchange also touches on dietary strategies, the evolutionary resistance of tumors, and growing concern that cuts to U.S. science funding could slow the kind of basic research that made this advance possible.

Therapy and Mechanism

  • Discussion centers on daraxonrasib, a drug targeting cancers with KRAS mutations, previously seen as “undruggable.”
  • Instead of blocking KRAS directly, it “glues” KRAS to another protein (CypA), sequestering it away from where it drives growth.
  • Posters note this represents a new drug modality (molecular glues / protein–protein interaction manipulators), potentially opening many future therapies.

Clinical Scope and Trials

  • The article’s “master switch” framing is called hyperbolic; commenters stress it likely applies to ~20% of tumors, though many of these are among the hardest-to-treat cancers.
  • Current data come from pancreatic cancer patients who failed first-line therapy; survival gains are measured in months on average, not years, but still viewed as meaningful.
  • Multiple clinical trials are underway: second-line and first-line pancreatic cancer, lung cancer, and combinations with other drugs; more trials are expected.
  • One comment claims the drug has passed phase 3 trials and that there is an access trial to broaden availability.
  • Side effects are described as “horrible,” and learning how to manage them is seen as a major next step.

Cancer Complexity and Resistance

  • Repeated emphasis that “cancer is not one thing”; different cancers and even regions of a single tumor can behave differently.
  • Comparisons to antibiotics and penicillin are discussed; consensus is that a universal “cure for cancer” is unlikely due to heterogeneity and rapid evolution within tumors.
  • Drug resistance and evolutionary pressure under therapy are highlighted as central challenges.

Debate on Value of Incremental Gains

  • Some express cynicism that non-curative drugs merely prolong dependence and profit; others strongly counter that even months or a few extra years—especially in aggressive cancers—are profound wins for patients and families.
  • Clinical trial participants are widely portrayed as crucial to progress, though there is disagreement on how much to celebrate incremental benefits.

Diet, Metabolism, and Anecdotes

  • One detailed anecdote describes combining chemotherapy and surgery for pancreatic cancer with a strict diet: eliminating sugar and animal products, guided by cancer’s reliance on glucose and glutamine.
  • The reported outcome: major tumor shrinkage, normalization of markers, good tolerance of chemo, and long-term cancer-free status, with relapse of markers when diet relaxed.
  • Others caution that such cases are anecdotal; without randomized controlled trials, dietary recommendations may help or harm and should not be treated as proven therapy.
  • There is brief mention of experimental “starving cancer” strategies (ketogenic diets plus drugs targeting glutamine), but only as exploratory ideas.

Alternative Research Directions

  • Michael Levin’s work on bioelectric signaling and its potential to start/stop cancer or drive regeneration via voltage patterns is mentioned as intriguing but still largely in early-stage and needing in vivo human results to gain traction.
  • Another thread on CRISPR-based cancer treatments is referenced as part of a broader landscape of parallel breakthroughs.

Science Funding and Politics

  • Several comments warn that US science and NIH funding are under political threat, with claims of slowed grant awards, politicized control of funding, restrictions on international collaboration, and greater uncertainty.
  • Others argue for cutting perceived bureaucratic or politically driven parts of the system, claiming favoritism in hiring and funding; critics respond that these claims lack evidence and that cuts are already harming core research.
  • Broader concern is expressed that undermining scientific infrastructure will slow exactly the kinds of advances represented by drugs like daraxonrasib.

Meta and Broader Implications

  • Many see this result as an important “baby step”: the first real hit on KRAS plus proof that previously “undruggable” targets can be tackled.
  • There is cautious optimism that AI and new drug design tools may accelerate similar breakthroughs in cancer and other diseases.